Updated March 29, 2020
Patients with a substance use disorder (SUD), mental illness or chronic pain are among those who may be acutely affected by interruptions in medical care, including interruptions in access to medications used as part of their treatment regimen. As the COVID-19 pandemic continues to challenge our health care system, the AMA encourages providers to use the information below as guidance to help ensure continuity of care for their patients.
1. Drug Enforcement Administration (DEA)
- General guide on prescribing controlled substances during a declared emergency via telemedicine: Applies to chronic pain patients and those stable on buprenorphine treatment for opioid use disorder (OUD), mental illness and chronic pain among other chronic conditions.
2. National Institute on Drug Abuse
The National Institute on Drug Abuse has alerted the research community that populations with Substance Use Disorders (SUDs) may be impacted particularly hard and details implications.
3. Substance Abuse and Mental Health Services Administration (SAMHSA)
In response to the COVID-19 pandemic, SAMHSA is offering several resources for mental and substance use disorder treatment providers and others. Included among the SAMHSA resources are:
- SAMHSA guidelines about opioids treatment programs (OTPs) prescribing take home treatment medication (March 16, 2020; updated March 19, 2020)
- SAMHSA FAQs: Provision of methadone and buprenorphine for the treatment of opioid use disorder in the COVID-19 emergency (March 19, 2020)
- SAMHSA OTP guidance for patients quarantined at home with the coronavirus
4. American Association for the Treatment of Opioid Dependence
American Association for the Treatment of Opioid Dependence has prepared a guidance for OTPs which includes useful information related to maintaining medication supply, facility infectious disease control standards, protecting workforces and patients, drug testing and more.
5. AMA Opioid Task Force
All physicians should be strongly encouraged to co-prescribe naloxone to any patients receiving opioids (and more so for those getting opioids and benzodiazepines).
